Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 620 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine Clear all
Completed Phase 2 Interventional

Trial of Buprenorphine/Naloxone for Opiate Dependence - 2

NCT00000353
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
19 Years to 57 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 19, 2026, 9:08 PM EDT
Withdrawn Phase 3 Interventional

Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS)

NCT04455802
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Buprenorphine or Placebo, Morphine or Placebo
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 19, 2026, 9:08 PM EDT
Recruiting Not applicable Interventional

Food Insecurity and Eating Behavior Among Adults Receiving Buprenorphine or Methadone Maintenance Treatment: Pilot Study 2

NCT07251283
View directory record Official record
Conditions
Food Security
Interventions
NE + Meal Delivery (NE+MD) intervention
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 19, 2026, 9:08 PM EDT
Recruiting Not applicable Interventional

Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated Treatment

NCT05711056
View directory record Official record
Conditions
Opioid Use, Opioid Abuse
Interventions
Sociobehavioral Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 19, 2026, 9:08 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail

NCT06593353
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorders
Interventions
Systems Analysis and Improvement Approach (SAIA)
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 110 Years
Enrollment
4,186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 19, 2026, 9:08 PM EDT
Completed Phase 1 Interventional

Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain

NCT02372591
View directory record Official record
Conditions
Opioid-Related Disorders, Chronic Pain
Interventions
Buprenorphine, Hydromorphone, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 19, 2026, 9:08 PM EDT
Terminated Phase 3 Interventional Results available

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

NCT01125917
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
84
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 19, 2026, 9:08 PM EDT
Active, not recruiting Not applicable Interventional

Neuromodulation and Cognitive Training in Opioid Use Disorder

NCT03773523
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Dependence, Opioid Abuse
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 19, 2026, 9:08 PM EDT
Terminated Phase 3 Interventional Results available

Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

NCT01135524
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
89
States / cities
Alabaster, Alabama • Birmingham, Alabama • Fairfield, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 19, 2026, 9:08 PM EDT
Completed Not applicable Interventional Results available

Computer Based Treatment for Cognitive Behavioral Therapy and Cooperative Pain Education and Self-Management

NCT05204576
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain
Interventions
CBT4CBT COPES
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Bridgeport, Connecticut • Danbury, Connecticut • Waterbury, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 19, 2026, 9:08 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation

NCT03420313
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone sublingual tablets
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 19, 2026, 9:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users

NCT01108679
View directory record Official record
Conditions
Opioid-related Disorders, Buprenorphine, HIV, Cognition, HIV Infections
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 19, 2026, 9:08 PM EDT
Recruiting Not applicable Interventional

Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons

NCT06999811
View directory record Official record
Conditions
Opioid Use Disorder, Pregnancy
Interventions
Empowering Pregnant Women and People Receiving medications for opioid use disorder (EMPWR), Medication monitoring (control)
Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 19, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder

NCT03787628
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Cannabidiol (CBD) 600 mg, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tarzana, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 19, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.

NCT03996694
View directory record Official record
Conditions
Respiratory Depression
Interventions
Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg, Oxycodone 30 mg, Oxycodone 60 mg, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 19, 2026, 9:08 PM EDT
Recruiting Not applicable Interventional

Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment

NCT07342504
View directory record Official record
Conditions
Alcohol Use Disorder, Opioid Use Disorder, Alcohol Use, Opioid Use
Interventions
Brief opioid-informed alcohol treatment
Behavioral
Lead sponsor
University of Notre Dame
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Notre Dame, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 19, 2026, 9:08 PM EDT
Recruiting Phase 2 Interventional

Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use

NCT06379984
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 19, 2026, 9:08 PM EDT
Completed Phase 3 Interventional

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

NCT00032955
View directory record Official record
Conditions
Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
15 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
6
States / cities
Rancho Mirage, California • Orlando, Florida • Pinellas Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 9:08 PM EDT
Completed Phase 3 Interventional

Distress Tolerance and Buprenorphine

NCT01556087
View directory record Official record
Conditions
Opioid Dependence
Interventions
Distress Tolerance, Health Education
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Oct 19, 2026, 9:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing MAT Engagement With Financial Incentives

NCT04585399
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Contingency management
Behavioral
Lead sponsor
Rowan University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 19, 2026, 9:08 PM EDT
Terminated Phase 2 Interventional Results available

Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD

NCT03852628
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Abuse
Interventions
2mg Buprenex and 380mg Vivitrol, Placebo (SL pill qd, IM injection q4weeks)
Drug
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
18 Years to 70 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 19, 2026, 9:08 PM EDT
Completed Not applicable Interventional

Incentivizing Buprenorphine-Naloxone Initiation in Emergency Departments

NCT03821103
View directory record Official record
Conditions
Opioid Use
Interventions
Training, Behavioral economic enhanced arm
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 19, 2026, 9:08 PM EDT
Completed Not applicable Interventional

Effect of Music on Cue Reactivity for Patients With Opioid Use Disorder

NCT06948890
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Music intervention, Silence
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 19, 2026, 9:08 PM EDT
Recruiting Not applicable Interventional

Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD

NCT06288711
View directory record Official record
Conditions
Opioid Use Disorder, Posttraumatic Stress Disorder
Interventions
Prolonged exposure therapy, Financial incentives, Treatment as usual
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 19, 2026, 9:08 PM EDT